Dr. Robert Arnold is a Professor in the Department of Drug Discovery and Development with adjuncts in Pathobiology at Auburn University and Small Animal Medicine and Surgery, University of Georgia, as well as Senior Scientist and Member of Experimental Therapeutics at the UAB O’Neal Comprehensive Cancer Center - an NIH Comprehensive Cancer Center. He obtained a Ph.D. (2004) in Pharmaceutical Sciences and completed postdoctoral training in cancer therapeutics and non-invasive imaging at the University at Buffalo and Roswell Park Cancer Institute. He has industrial (Wyeth-Ayers Research) and academic experience in preclinical and translational development of therapies to human clinical studies. The focus of his research is the development and utilization of nanomedicines and alternate dosing schedules to improve the treatment of cancers. Specifically, he is interested in developing composite nanomedicines to improve drug delivery to primary tumors and metastatic disease and utilizing pharmacokinetic–pharmacodynamics (PK/PD) modeling and simulation to optimize drug dosing schedules. Furthermore, he is using a variety of contemporary molecular techniques to gain insights into how tumor microenvironment and alternate dosing schedules can alter the disposition and activity of drugs and nanomedicines. Dr. Arnold’s research is(has) been supported by the National Institute of Biomedical Imaging and Bioengineering and the National Cancer Institute at the NIH, and a variety of private and public institutions. He has worked for and consults for a number of pharmaceutical companies and currently serves as an ad-hoc member of the Developmental Therapeutics (DT) NIH study section and serves on a number of special emphasis panels.